Apellis Pharmaceuticals, Inc. (APLS) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Apellis Pharmaceuticals Inc (APLS) 3-Minute Overview > **💡 One-Sentence Summary** > > Simply put, Apellis is a biotech company trying to turn a high-margin rare-disease and eye-disease drug platform into a durable commercial business—but the story still hinges on execution more than certainty. > **📍 Basic Profile** > > Market Cap **$2.18 billion** · Biotechnology · NASDAQ NMS - GLOBAL MARKET · Price **$40.23** > **⚡ 3 Things You Should Know** > > 1. 💰 **Commercial model is finally showing real operating leverage:** Gross margin is an exceptional **89.81%**, and Apellis has reached a slim **2.23% net margin** with **5.52% operating margin**—that matters because biotech stories often stay “promising” for years, while this one is at least starting to look like an actual business. > > 2. 📈 **Growth has been very strong, but the ride is not smooth:** 3-year revenue growth of **137%** is eye-catching, yet recent earnings have been mixed with both big beats and notable misses. In other words, demand is there, but quarter-to-quarter execution and expectations can swing hard. > > 3. ⚠️ **The stock price is already pricing in a lot of optimism:** Shares sit essentially at the **52-week high**, and the **97.6x TTM PE** says the market is betting the recent profitability inflection is real and expandable. If growth or margins wobble, this kind of setup can correct fast. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Medium✋ | Net margin 2.23%, profitable but still thin for comfort | > | Growth Rate | Fast🚀 | Revenue growth 137% (3Y basis), clearly high-growth | > | Financial Health | Moderate💛 | Debt/equity 123%, but liquidity is solid with current ratio 3.14 | > | Valuation | Expensive | PE 97.58x | ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Apellis develops and sells specialty biotech therapies to patients and healthcare providers, making money through drug sales from its commercialized products. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Commercial drug sales | [Data unavailable] | ↑ | Revenue growth suggests commercialization is scaling | | Pipeline / other | [Data unavailable] | → | Still important strategically, but current thesis is mainly about marketed products | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 89.81% | Top tier | Very high gross margin; once revenue scales, earnings can improve fast | | Net Margin | 2.23% | Below Average | Barely profitable, so the business is still proving sustainability | | ROE | 8.20% | Average | Positive, but not yet strong enough to call this a mature high-return business | --- #### 📈 How's the Growth? **Growth Assessment:** High Growth | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | 137% (3Y) | [Data unavailable] | Strong, but exact recent annual pace unavailable | | Profit Growth | [Data unavailable] | [Data unavailable] | Mixed, based on earnings surprises | **Growth Quality:** > What's interesting is that growth appears tied to real product commercialization rather than purely financial engineering. That said, biotech growth can look explosive early on and still be fragile, especially when it depends on a small number of products and changing physician adoption. --- #### 💰 Financial Health Check **One Sentence:** Think of it like someone with good cash in the bank and decent short-term flexibility, but still carrying meaningful debt and not yet earning enough to make that debt feel easy. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | Debt/Equity 123.01% | <60% safe | ⚠️High | | Current Ratio | 3.14 | >1.5 healthy | ✅Safe | | Cash Flow | -$5.21/share | >0 | ⚠️Volatile | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $16.10 - 52-Week High: $40.45 - Current: $40.23, **Very close to high** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | | | ●(**99%** position) | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE 97.58x | [Data unavailable] | [Data unavailable] | | vs Peers | PE 97.58x | Industry avg [Data unavailable] | Likely rich for a still-early profitable biotech | **What the Current Valuation is Betting On:** > Basically, the market is betting that Apellis has crossed from “story stock” into “scaled commercial biotech,” and that current products can keep growing without a major stumble in uptake, safety perception, reimbursement, or competition. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-03-30 | Seeking Alpha article discussed **Biogen acquiring Apellis at $41/share** | Neutral/Speculative + important because the stock is already trading near that level, which can cap upside if deal expectations fade | | 2026-02-25 | Q4 2025 earnings-related coverage highlighted mixed revenue and an earnings beat narrative | Mixed + suggests the business is improving, but not in a clean straight line | | 2026-03-17 | Cantor Fitzgerald maintained Overweight but cut price target to **$31** | Negative/Mixed + support remains, but lower target shows analysts still see execution risk | | 2026-03-04 | JPMorgan maintained Overweight and raised target to **$37** | Positive + sentiment improved, though even that target is below the current share price | ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 89.81% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | 2.23% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | 8.20% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | ↑ | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2025-12-31 | -$0.39 | -$0.47 | -21.0% Miss 😟 | | 2025-09-30 | $1.21 | $1.67 | +38.1% Beat 😀 | | 2025-06-30 | -$0.48 | -$0.33 | +31.0% Beat 😀 | | 2025-03-31 | -$0.37 | -$0.74 | -101.4% Miss 😟 | **Earnings Trend Interpretation:** The pattern here is not “steady execution,” but volatility. Two strong beats show upside when commercialization clicks, while two ugly misses remind you that forecasting this business is still hard and investor confidence can shift quickly. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 20 firms | 69.0% | | Hold | 8 firms | 27.6% | | Sell | 1 firm | 3.4% | **Target Price:** $20 ~ $44 (rough visible range from recent analyst updates) **vs Current Price:** from **-50% downside risk** to about **+9% upside**, depending on whose model you trust **Insider Activity:** Net activity appears **mixed and mostly compensation/award-related**, not a clean conviction signal > Worth noting: several filings are coded as **A/G/M** (awards, gifts, option-related moves), which are less informative than open-market buys. There was at least one small sale, but the data does not show a strong wave of insiders rushing for the exits. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Valuation Risk:** The stock is trading near its 52-week high with a very high PE → If commercial growth slows even a bit, the multiple could compress sharply 2. **Execution Risk:** Earnings have been inconsistent quarter to quarter → If product demand, launch execution, or reimbursement disappoints, sentiment could reverse fast 3. **Balance Sheet / Cash Flow Risk:** Debt is elevated and cash flow per share is negative → If profitability doesn’t broaden, financing flexibility could become more important than investors expect ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Apellis is a commercial-stage biotech built around high-value specialty drugs, and the market is starting to treat it less like a pure pipeline bet and more like an operating company. > > **Key strength:** The big positive is that gross margin is extremely high and revenue growth has been strong enough to push the company into at least modest profitability. > > **Key risk:** The main concern is that the stock now reflects a lot of optimism, while earnings, cash flow, and execution still look too uneven to call this a fully de-risked story. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis